OTCMKTS:SPHRY Starpharma (SPHRY) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free SPHRY Stock Alerts $0.92 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.92▼$0.9250-Day Range$0.82▼$0.9652-Week Range$0.77▼$3.30VolumeN/AAverage Volume732 shsMarket Capitalization$37.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get Starpharma alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Starpharma Stock (OTCMKTS:SPHRY)Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.Read More SPHRY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPHRY Stock News HeadlinesMarch 14, 2024 | wsj.comStarpharma Holdings Ltd. ADRFebruary 19, 2024 | markets.businessinsider.comStarpharma's VivaGel Approval Denied By FDAApril 27, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 18, 2024 | msn.comASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pcJanuary 19, 2024 | morningstar.comStarpharma Holdings Ltd SPLJanuary 6, 2024 | afr.comStarpharma Holdings LimitedNovember 29, 2023 | finance.yahoo.comStarpharma Holdings Limited (SPHRY)November 8, 2023 | investing.comStarpharma Holdings (SPHRY) Earnings Dates & ReportsApril 27, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.July 27, 2023 | seekingalpha.comStarpharma: Patience Needed, But A Lot To LikeJune 9, 2023 | msn.comThe Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreakOctober 24, 2022 | finance.yahoo.comVIRALEZE Nasal Spray to be distributed in Hong Kong and MacauSeptember 12, 2022 | finance.yahoo.comStarpharma presents compelling data in Prostate Cancer at ESMOAugust 10, 2022 | finance.yahoo.comStarpharma signs new DEP® agreement with MSDJuly 20, 2022 | finanznachrichten.deStarpharma: VIRALEZE Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral ExposureJanuary 12, 2022 | nasdaq.comStarpharma Holdings Ltd. ADR (SPHRY)December 13, 2021 | msn.comWhat is happening to the Starpharma (ASX:SPL) share price today?December 6, 2021 | msn.comStarpharma (ASX:SPL) share price shoots 6% higher on Roche agreementNovember 19, 2021 | msn.comWhy is the Starpharma (ASX:SPL) share price trading at 52-week lows?October 28, 2021 | markets.businessinsider.comPerth businesswoman Kim Tran launches new business, scores supply deal with StarpharmaOctober 26, 2021 | msn.comStarpharma (ASX:SPL) share price lifts on supply and distribution dealOctober 8, 2021 | finance.yahoo.comVIRALEZE™ antiviral nasal spray launched in ADMENTA Italia Group pharmacies in ItalySeptember 15, 2021 | apnews.comUS Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma’s phase 2 clinical-stage cancer treatmentsSeptember 15, 2021 | finance.yahoo.comUS Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatmentsAugust 26, 2021 | msn.comStarpharma (ASX:SPL) share price tanks 3% on 67% revenue dropJuly 26, 2021 | msn.comWhy the Starpharma (ASX:SPL) share price is racing 7% higher todaySee More Headlines Receive SPHRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolOTCMKTS:SPHRY CUSIPN/A CIKN/A Webwww.starpharma.com Phone(138) 532-2700Fax61-3-9510-5955Employees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.83 million Price / Sales13.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book1.61Miscellaneous Outstanding Shares41,200,000Free FloatN/AMarket Cap$37.90 million OptionableNot Optionable Beta1.19 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Justin CahillCFO & Company SecretaryMs. Cheryl Maley B.Sc. (Age 55)M.B.A., CEO, MD & Director Key CompetitorsData Knights AcquisitionNASDAQ:DKDCAbioAffinity TechnologiesNASDAQ:BIAFHedgePath PharmaceuticalsOTCMKTS:HPPIAIkido PharmaNASDAQ:AIKIInotivNASDAQ:NOTVView All Competitors SPHRY Stock Analysis - Frequently Asked Questions How have SPHRY shares performed in 2024? Starpharma's stock was trading at $1.2440 at the beginning of the year. Since then, SPHRY shares have decreased by 26.0% and is now trading at $0.92. View the best growth stocks for 2024 here. Are investors shorting Starpharma? Starpharma saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 2,700 shares, a drop of 70.0% from the March 15th total of 9,000 shares. Based on an average daily trading volume, of 1,400 shares, the days-to-cover ratio is currently 1.9 days. View Starpharma's Short Interest. How do I buy shares of Starpharma? Shares of SPHRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SPHRY) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Starpharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.